EXCLUSIVE: Longeveron Announces Phase 1 Clinical Study Of Lomecel-B Injection In Hypoplastic Left Heart Syndrome Patients Met Primary Safety Endpoint With No Major Adverse Cardiac Events OR Treatment-Related Infections During First Month Post-Treatment